AstraZeneca and MSD's Koselugo (selumetinib) Receive the EU's Approval for Neurofibromatosis Type 1 and Plexiform Neurofibromas
Shots:
- The conditional approval is based on P-II SPRINT Stratum 1 trial assessing selumetinib (PO- bid) as monothx. in pediatric patients aged >3yr. with NF1-related inoperable PNs. The trial was sponsored by NCI CTEP- conducted under a research & development agreement b/w NCI & AstraZeneca with additional support from NTAP
- The trial showed a reduction in size of tumors with ORR (66%) in children- reduction in pain- improvement in QoL. Safety & efficacy data of the study with longer follow up will be provided as one of conditional approval
- The therapy is approved in the US & other countries for NF1 & symptomatic- inoperable PN while other regulatory submissions of the therapy are ongoing
Ref: AstraZeneca | Image: New Europe
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com